USP39 promotes ovarian cancer malignant phenotypes and carboplatin chemoresistance

LINGZHI WANG1*, TANXIU CHEN2*, XUKUN LI3, WEI YAN4, YANHUI LOU1, ZHIHUA LIU3, HONGYAN CHEN3 and ZHUMEI CUI1

1Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266061; 2Department of Science and Education, Jiangxi Key Laboratory of Translational Cancer Research, Jiangxi Cancer Hospital, Nanchang, Jiangxi 330029; 3State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021; 46th Department of Internal Medicine, Jiangxi Cancer Hospital, Nanchang, Jiangxi 330029, P.R. China

Received October 19, 2018; Accepted May 24, 2019

DOI: 10.3892/ijo.2019.4818

Abstract. Ubiquitin-specific protease 39 (USP39), as one of the deubiquitinating enzymes (DUBs), exhibits aberrant expression and has oncogenic functions in several types of cancer. However, the function and underlying molecular mechanisms of action of USP39 in ovarian cancer remain largely undetermined. The present study thus aimed to investigate whether USP39 is a promising tumor-associated gene and whether it could be a viable target for overcoming chemotherapeutic resistance in ovarian cancer. The present study identified that USP39 was highly expressed in ovarian cancer samples with carboplatin resistance. A series of functional assays revealed that the knockdown of USP39 in ES2 and SKOV3 cells significantly decreased cell proliferation, induced cell cycle arrest at the G2/M phase and impaired the cell colony formation ability. USP39 deficiency enhanced the carboplatin-induced apoptosis of the SKOV3 cells via the activation of poly-ADP ribose polymerase and caspase-3. USP39 knockdown led to the inhibition of cell migration and invasion. The opposite effects were observed when USP39 was overexpressed in the ES2 and SKOV3 cells. In vivo animal models revealed that the subcutaneous transplantation and intraperitoneal injection of USP39-overexpressing ES2 cells increased tumor burden with or without treatment with carboplatin. However, the knockdown of USP39 suppressed SKOV3 cell growth in vivo. Mechanistic analyses also demonstrated that USP39 induced the phosphorylation of extracellular signal-regulated kinase and AKT and increased the expression of epidermal growth factor receptor and cyclin B1. Collectively, the findings of this study suggest that USP39 may play a vital role in regulating ovarian cancer malignant phenotypes and carboplatin resistance. Therefore, USP39 may prove to be a promising therapeutic target for patients with ovarian cancer.

Introduction

With a 5-year survival rate of <25%, ovarian cancer represents one of the most aggressive and challenging types of cancer as regards treatment. Ovarian cancer is the leading cause of cancer-associated mortality among all gynecological tumors, and the majority of patients with this type of cancer are diagnosed at advanced and metastatic stages (1,2). Despite advances in systemic chemotherapies, including cisplatin and carboplatin, which are widely used at present, the prognosis of patients with ovarian cancer remains remarkably poor due to high incidences of chemoresistance (1,3). To date, multiple molecular mechanisms involved in ovarian tumorigenesis and chemoresistance have been proposed; however, no reliable biomarkers have been identified as predictors of an individual's chemotherapeutic response (1,4). Thus, the identification of leading factors mediating chemoresistance and the elucidation of the underlying mechanisms is of utmost importance, in order to develop novel and effective therapeutic strategies for preventing or reversing therapeutic resistance.

Ubiquitin-specific peptidase 39 (USP39) encodes a 65 kDa SR-associated protein, which has been demonstrated to be involved in RNA splicing as a component of the U4/U6-U5 tri-small nuclear ribonucleoprotein (snRNP) (5,6). Zebrafish USP39 displays the ability to recruit the tri-snRNPs to the pre-spliceosome and target retinoblastoma (rb1) and E2F transcription factor 4 (e2f4) expression to regulate embryonic...
pituitary homeostasis (7). In accordance with its previous reported role in messenger RNA (mRNA) processing, USP39 has also been implicated as a key factor in regulating the splicing of Aurora B and other mRNAs to maintain mitotic spindle checkpoint integrity (8). Notably, despite being classified as a member of the deubiquitinating enzymes (DUBs), USP39 is fully deprived of protease activity (9). Recent evidence suggests that USP39 plays a vital role in regulating the malignant phenotypes of various cancer types (1,5). For instance, the overexpression of USP39 promotes tumorigenesis in prostate cancer; mechanistic investigations have demonstrated that the silencing of USP39 downregulates epidermal growth factor receptor (EGFR) expression by inducing a splicing defect via the retention of intron 2 between exons 2 and 3, thus affecting the expression of the 3' end of EGFR (10). The silencing of USP39 has been shown to inhibit cell growth and colony formation of breast cancer in vitro (11). Additionally, USP39 has been identified as an indispensable gene for the survival of KRAS-dependent lung cancer and colorectal carcinoma (8). However, little is known about the biological functions and the role of USP39 in the chemosensitivity of human ovarian cancer.

The present study thus aimed to investigate the roles of USP39 in ovarian cancer. USP39 was found to be highly expressed in carboplatin-resistant ovarian cancer tissues compared with carboplatin-sensitive tissues. Functional assays demonstrated that USP39 plays a crucial role in regulating malignant phenotypes and chemoresistance in ovarian cancer cells. In addition, USP39 confers ovarian cancer cell chemoresistance via the AKT/extracellular signal-regulated kinase (ERK) signaling pathway. Therefore, the findings of this study suggest that USP39 may be a potential molecular target for ovarian cancer therapy, and may provide novel insight into the progression and chemotherapeutic resistance of ovarian cancer.

Materials and methods

Clinical specimens. In the present study, a total of 119 clinical specimens from patients with ovarian cancer who underwent initial surgical treatment at the Department of Gynecologic Oncology of the Chinese Academy of Medical Sciences Cancer Hospital (Beijing, China) were collected from May 2007 to January, 2013. All patients provided informed consent to participate in the study. This study was approved by the Ethics Committee of the Chinese Academy of Medical Sciences Cancer Hospital.

Immunohistochemistry (IHC). IHC was performed as previously described (12). USP39 expression was assessed using a rabbit monoclonal antibody (ab131244; Abcam) at a 1:50 dilution at 4°C overnight, according to the manufacturer’s instructions. As negative controls, sections incubated with rabbit immunoglobulin G (1:1000; ab6721; Abcam) instead of primary antibodies were used. Following incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies (OriGene Technologies, Inc.) at room temperature for 1 h, the positive signals were visualized with 3,3'-diaminobenzidine (OriGene Technologies, Inc.) as a substrate. All slides were scanned with an Aperio scanning system (Aperio Group, LLC) and Aperio Image Scope software (version 10.2.2.2317, Aperio Technologies) was employed for the quantitative analysis of USP39 protein expression. For analysis, 4-6 different areas of the slide were randomly selected. The intensity score was graded with a score ranging from 0 to 3 according to the percentage of positively stained tumor cells. When 0-10% of tumor cells were stained, a score of 0 was given; when 10-25% of tumor cells were stained, a score of 1 was given; when 25-50% of tumor cells were stained, a score of 2 was given; and when 50-100% of tumor cells were stained, a score of 3 was given. Scores of 0 and 1 were considered to represent a low expression, while scores of 2 and 3 were considered to represent a high expression. The staining results of USP39 were evaluated according to the scoring criterion reported in a previous study (13).

Cell culture. The human ovarian cancer cell lines ES2, SKOV3 and the 293T cells were purchased from the American Tissue Culture Collection. The human ovarian cancer cell lines were cultured in RPMI-1640 (Gibco, Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific, Inc.), 100 U/ml ampicillin (Life Technologies, Gibco) and 100 µg/ml streptomycin (Life Technologies, Gibco). The 293T cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS, 100 U/ml ampicillin and 100 µg/ml streptomycin. All cells were cultured at 37°C in 5% CO₂.

Construction of plasmids, lentivirus packaging and transfection. For the stable knockdown of USP39, two small hairpin RNA (shRNA) sequences (shUSP39#1 and shUSP39#2) targeting USP39 were respectively inserted into pSIH1-H1-Puro (In vitrogen, Thermo Fisher Scientific, Inc.), and sh-green fluorescence protein (GFP) (In vitrogen, Thermo Fisher Scientific, Inc.) was used as control. The two USP39 shRNA sequences were as follows: 5'‑GTACTTTCAAGGCGGGGT‑3' (shUSP39#1) and 5'‑ACAGCAGCTACAAGAAT‑3' (shUSP39#2). shRNA plasmids were transfected into the 293T cells together with 3 packaging plasmids (3 µg PLP1, 3 µg VSVG and 3 µg PLP2) (In vitrogen, Thermo Fisher Scientific, Inc.) using Lipofectamine 2000 (In vitrogen; Thermo Fisher Scientific, Inc.) with OPTI-MEM (Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS). The virus-containing media were pooled at 48 h after transfection, centrifuged under 800 x g for 10 min at 4°C and filtered by passing through a 0.45-µm filtration device (EMD Millipore). Viral supernatant was added in a 1:3 dilution to previously seeded cell lines, supplemented with 5 µg/ml of polybrene (EMD Millipore). Stably transduced cells were selected with puromycin at a final concentration of 1 µg/ml. For the stable overexpression of USP39, full-length complementary DNA of human USP39, which was generated by polymerase chain reaction (PCR) amplification, was cloned between the XhoI and XbaI sites of pLVX-IRES-Neo (In vitrogen, Thermo Fisher Scientific, Inc.) to prepare a constitutive lentiviral vector. A total of 8x10⁶ 293T cells were seeded in 100-cm² plates. pLVX-IRES-Neo or pLVX-IRES-Neo-USP39 lentiviral vectors (7.5 µg) and the corresponding packaging plasmid (6.5 µg pCMV Δ8.91, 3.5 µg VSVG and 2.5 µg PLP2) were added to a mixture of Lipofectamine 2000 (In vitrogen; Thermo Fisher Scientific, Inc.) with OPTI-MEM (Thermo Fisher Scientific, Inc.). Following a similar transfection procedure as the one described...
above, stably transduced cells were selected with G418 (Sigma-Aldrich) at a final concentration of 400 μg/ml. At 48 h following transfection, knockdown and overexpression efficiencies were evaluated by reverse transcription-quantitative PCR (RT-qPCR) and western blot analysis.

**Cell proliferation assay.** To quantify cell proliferation, 100 μl stably transected cells at a density of 1x10^4 cells/ml (n=6) were seeded in 96-well plates. A Cell Counting kit-8 (CCK-8) assay kit was used to detect cell viability at 5 time points. The cells were cultured in 100 μl/well fresh medium mixed with CCK-8 solution (10:1) (Dojindo Molecular Technologies, Inc.) and incubated for 1 h at 37°C. The optical density values were then measured at 450 nm using a spectrophotometer (Bio-Rad).

**Apoptosis assay.** The ES2 and SKOV3 cells were analyzed for apoptosis using an Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) kit [Multisciences (Lianke) Biotech Co., Ltd.]. Briefly, the cells were seeded at 5x10^5 cells/well in 6-well plates in triplicate. Followin 24 h of incubation with carboxplatin, the cells were harvested through trypsinization and washed twice with cold PBS. The cells were centrifuged at 3,000 x g at room temperature for 5 min. The supernatant was then discarded and the pellet was resuspended in 500 μl 1X binding buffer. Finally, the cells were incubated with 5 μl FITC-conjugated Annexin V and 10 μl of PI for 5 min at room temperature in the dark. The samples were analyzed by a FACSCalibur flow cytometer (BD Biosciences).

**Analysis of the cell cycle.** For cell cycle analysis, the cells were harvested and fixed with 70% ethanol for 18 h at -20°C upon digestion with 0.05% trypsin. Upon washing with PBS and collecting the fixed cells by 800 x g centrifugation at 4°C for 5 min, samples were resuspended with 500 μl DNA staining solution and then incubated in 37°C for 30 min. Analysis was performed on a FACSCalibur flow cytometer (BD Biosciences).

**RT-qPCR analysis.** Total RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The cDNA was synthesized by the FastQuant RT kit [TIANGEN Biotech (Beijing) Co. Ltd.] using 100 ng of total RNA. Quantitative analysis was performed with diluted cDNA combined with the SYBR-Green PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.), forward and reverse primers, and RNase-free water. For the primer sequences, see Table S1. The reactions were conducted according to the following parameters: 50°C for 2 min, 95°C for 10 min, 40 cycles at 95°C for 10 sec, at 60°C for 20 sec and at 72°C for 30 sec. The relative mRNA expression in each sample was calculated using the 2^-ΔΔCT method (14).

**Western blot analysis.** Total protein was extracted from whole cells using ice-cold cell lysis buffer (1% Triton X-100; 10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.25% sodium deoxycholate; 5 mM EDTA, pH 7.4) and assayed for protein concentration by a bicinchoninic acid assay (Pierce). Samples containing 15 μg of protein were separated by 8-12% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Merck KGaA). After blocking with 5% skimmed milk powder for 1 h at room temperature, the membranes were incubated with antibodies against USP39 (1:1,000; ab131244; Abcam), caspase-3 (1:100; #9661; Cell Signaling Technology, Inc.), poly-ADP ribose polymerase (PARP) (1:1,000; #9542; Cell Signaling Technology, Inc.) and β-actin (1:5,000; A5316; Sigma-Aldrich; Merck KGaA) overnight at 4°C, followed by incubation with a appropriate HRP-linked secondary antibody (1:2,000; #7074/#7076; Cell Signaling Technology, Inc.) at room temperature for 1 h. Samples were detected with an enhanced chemiluminescence detection system (Pierce; Thermo Fisher Scientific, Inc.).

**Colony formation assay.** For the colony formation assay, lentivirus-infected cells were seeded evenly in 6-well plates at an initial density of 2,000 cells/well and cultured in a 5% CO2 incubator for 10 days at 37°C. The cells were washed with ice-cold PBS, fixed with 4% paraformaldehyde (PFA), stained with crystal violet at room temperature for 30 min and rinsed 3 times with double distilled H2O.

**Wound healing assay.** The cells were plated until they reached 90% confluence in 6-well plates. Cell monolayers were scratched with 200-μl pipette tips. Upon forming wound gaps, the cells were washed with PBS twice to remove floating cells and cultured in serum-free medium. Cell migration into the wound area was observed under an inverted microscope (Leica Microsystems) at different time points. The speed of wound closure was analyzed by measuring the distance of the migrating cells from different areas for each wound.

**Cell migration and invasion assays.** For the cell migration assay, cells (2x10^4), which has been resuspended in 100 μl serum-free medium, were added to the upper chambers of a Transwell plate (Corning Inc.). The lower chambers were filled with 600 μl RPMI-1640 complete medium containing 10% FBS. Following 24 h of incubation, the cells were fixed with 4% PFA for 30 min and stained with 0.1% crystal violet at room temperature for 1 min. After washing gently with water, the cells were imaged and counted under a microscope (Leica Microsystems). For the cell invasion assay, Matrigel (Sigma-Aldrich; Merck KGaA) was diluted from 5 mg/ml to 1 mg/ml by serum free-cold RPMI-1640. The upper chambers of the Transwell plates were pre-coated with 100 μl of the diluted Matrigel. The subsequent steps of the procedure were the same as those for the migration assay.

**Subcutaneous xenograft models.** Pathogen-free female BALB/c nude mice (age, 5-6 weeks; weight, 18-22 g, 6 mice per group) were provided standard laboratory chow and allowed free access to water, unless otherwise stated, in a climate-controlled room with a 12-h light/12-h dark cycle at the Animal Experiment Center of Cancer Hospital, Chinese Academy of Medical Sciences. Animal studies were approved by the Animal Care and Use Committee of Cancer Hospital, Chinese Academy of Medical Sciences. All procedures involving animals were conducted according to the guidelines for the care and use of laboratory animals. A total of 5x10^5 stably transected ES2 cells were resuspended in 100 μl normal saline and injected.
subcutaneously into the flank of each mouse with a 28G syringe. At 3 days post-inoculation, carboplatin was administered to the mice by intraperitoneal injection at a dose of 50 mg/kg every 3 days for 3 consecutive times as described previously (15). Tumors were measured using an electronic caliper twice per week, and tumor volume was calculated using the formula: Volume = (length x width^2)/2. All mice were sacrificed by cervical dislocation at 21 days post-injection. Tumor samples were fixed in formalin for paraffin embedding and sectioned into 4μm slides for IHC analyses. The sections were incubated with antibodies against USP39 (1:50; ab131244; Abcam) and cleaved caspase-3 (1:50; #9579; Cell Signaling Technology, Inc.) to measure the expression of USP39 and cleaved caspase-3.

**Statistical analysis.** Statistical analyses were conducted using Prism software 6 (GraphPad Software, Inc.). The associations between USP39 expression and the patient clinicopathological data were assessed using a Chi-square test. All data are presented as the means ± standard error of the mean of ≥3 independent experiments. For 2-group comparison, analyses were performed with a Student's unpaired t-test (two-tailed). For multiple experiments, statistical analyses were performed with one-way ANOVA with Tukey's post hoc test. All experiments other than histological examinations were repeated ≥2 times. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**USP39 is overexpressed in ovarian cancer tissues and is associated with carboplatin resistance.** USP39 expression was analyzed in carboplatin-sensitive and carboplatin-resistant human ovarian cancer tissues by IHC. The results revealed that USP39 was primarily expressed in the nucleus, but rarely in the cytoplasm (Fig. 1). In the carboplatin-resistant group, 60.71% of the specimens presented a strong positive expression vs. 41.27% in the carboplatin-sensitive group (P=0.034), determined by a Chi-square test (Table I). Subsequently, we analyzed whether the expression of USP39 can influence the clinicopathological characteristics of patients with ovarian cancer. As shown in Table I, USP39 expression was not associated with age, residual tumor size, level of cancer antigen 125 in primary tumors, International Federation of Gynecology and Obstetrics stage or tumor grade. These results indicate that high expression levels of USP39 in ovarian cancer tissues may be closely associated with the development of carboplatin resistance.

**USP39 promotes cell proliferation and colony formation by inducing cell cycle phase arrest in ovarian cancer cells.** To verify the role of USP39 in ovarian cancer cells, the ES2 and SKOV3 cell lines were transduced with shUSP39s or shGFP lentiviruses. The inhibitory effects of shUSP39s on its endogenous expression in the ES2 and SKOV3 cells were determined by RT-qPCR and western blot analysis (Fig. 2A and B). To examine the effects of USP39 on cell proliferation, a CCK-8 assay was performed. As shown in Fig. 2C, the proliferative rate of the ES2 and SKOV3 cells was significantly lower in shUSP39s-transduced cells compared with the shGFP control cells. To further characterize the effects of USP39 on the cell proliferative capability, a colony formation assay was employed. As depicted in Fig. 2D, upon the knockdown of USP39, the capacity of colony formation of the ES2 and SKOV3 cells was substantially reduced. To elucidate the mechanisms through which USP39 modulates cell proliferation and colony formation, cell cycle distribution analysis was employed. The cell percentage in the G2/M phase was increased by USP39 knockdown in the SKOV3 cells, suggesting that cell growth suppression may be associated with increased G2/M phase arrest (Fig. 2E). Cell cycle-associated protein analysis also revealed that the expression of cyclin B1 was suppressed following USP39 knockdown (Fig. 2F). The overexpression of USP39 in the ES2 cells indicated that USP39 significantly increased the cell proliferation and colony formation capacity of ES2 cells (Fig. 3). Taken together, these data support the important role of USP39 in regulating the proliferation of ovarian cancer cells.
Table I. Association between the expression of USP39 and the patient clinicopathological features in the ovarian cancer tissue arrays.

<table>
<thead>
<tr>
<th>Clinical variable</th>
<th>Patients</th>
<th>USP39 expression [no. (%)]</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cases</td>
<td>119</td>
<td>Low: 59 (49.58) High: 60 (50.42)</td>
<td>0.344</td>
</tr>
<tr>
<td>Age at diagnosis (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥60</td>
<td>15</td>
<td>Low: 42.86 High: 20 (57.14)</td>
<td>0.444</td>
</tr>
<tr>
<td>&lt;60</td>
<td>44</td>
<td>Low: 52.38 High: 40 (47.62)</td>
<td>0.344</td>
</tr>
<tr>
<td>Residual tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥2</td>
<td>8</td>
<td>Low: 44.44 High: 10 (55.56)</td>
<td>0.636</td>
</tr>
<tr>
<td>&lt;2</td>
<td>51</td>
<td>Low: 50 (50.50) High: 50 (49.50)</td>
<td>0.866</td>
</tr>
<tr>
<td>Level of CA125 in primary tumors (U/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥500</td>
<td>46</td>
<td>Low: 50.00 High: 46 (50.00)</td>
<td>0.866</td>
</tr>
<tr>
<td>&lt;500</td>
<td>13</td>
<td>Low: 48.15 High: 48.15</td>
<td>0.788</td>
</tr>
<tr>
<td>Recurrent type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carboplatin-sensitive</td>
<td>37</td>
<td>Low: 58.73 High: 26 (41.27)</td>
<td>0.034</td>
</tr>
<tr>
<td>Carboplatin-resistant</td>
<td>22</td>
<td>Low: 39.29 High: 34 (60.71)</td>
<td>0.034</td>
</tr>
<tr>
<td>FIGO stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>45</td>
<td>Low: 48.91 High: 47 (51.09)</td>
<td>0.866</td>
</tr>
<tr>
<td>IV</td>
<td>14</td>
<td>Low: 51.85 High: 48.15</td>
<td>0.788</td>
</tr>
<tr>
<td>Tumor grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1/G2</td>
<td>8</td>
<td>Low: 47.06 High: 9 (52.94)</td>
<td>0.881</td>
</tr>
<tr>
<td>G3</td>
<td>50</td>
<td>Low: 49.02 High: 50.98</td>
<td>0.881</td>
</tr>
</tbody>
</table>

Values in bold indicate statistical significance (P<0.05). USP39, ubiquitin-specific protease 39.

Figure 2. Effect of USP39 knockdown on the growth of ES2 and SKOV3 cell lines. (A) Reverse transcription-quantitative polymerase chain reaction analysis of the messenger RNA levels of USP39 in shGFP and shUSP39-transduced ES2 and SKOV3 cell lines. β-actin was used as a reference gene. (B) Identification of knockdown efficiency in shGFP and shUSP39-transduced ES2 and SKOV3 cell lines by western blot analysis. β-actin was used as a loading control. (C) The cell proliferative capability was obviously suppressed upon USP39 silencing in ES2 and SKOV3 cells, as measured by Cell Counting kit-8 assay. (D) The number of colonies was significantly decreased following USP39 knockdown in ES2 and SKOV3 cells. (E) USP39 knockdown induced G2/M phase arrest in SKOV3 cells. (F) Western blot analysis of changes in the expression of cell cycle-associated proteins upon knockdown of USP39 in SKOV3 cells. Data represent the means ± standard error of the mean of 3 independent experiments. shGFP, cells infected with shGFP; shUSP39, cells infected with USP39 shRNA. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, compared with the shGFP group. USP39, ubiquitin-specific protease 39; sh, small hairpin; GFP, green fluorescent protein.
Knockdown of USP39 suppresses ovarian cancer cell migration and invasion. Previous studies have reported that USP39 is a potential target for several types of cancer (5,6). To explore the possibility that USP39 activity may be involved in the metastatic behaviors of ovarian cancer cells, migration and invasion assays were performed in vitro. USP39 knockdown significantly suppressed the migration and invasion of ES2 cells (Fig. 4A and B). Similarly, the capacity of wound healing was suppressed in SKOV3 cells (Fig. 4C and D) by USP39 knockdown. These findings suggest that USP39 plays a critical role in the metastatic behavior of ovarian cancer cells.
markedly decreased in the SKOV3 cells in which USP39 was silenced and increased in the USP39-overexpressing ES2 cells compared with their respective control cells (Fig. 4C and D). These results indicate that USP39 plays a potential role in the induction of cell migration and invasion in ovarian cancer.

**USP39 is involved in the regulation of AKT and ERK signaling pathways.** To ascertain the regulatory mechanisms of action of USP39 as regards the tumorigenesis of ovarian cancer, multiple signaling pathways were analyzed in the ES2 cells upon altering USP39 expression. As shown in Fig. 5, USP39 knockdown markedly decreased the expression of EGFR, phosphorylated (p)-ERK and p-AKT. On the contrary, the expression levels of EGFR, p-ERK and p-AKT were increased upon the overexpression of USP39.

Reduced USP39 levels sensitizes ovarian cancer cells to carboplatin treatment. Based on the aforementioned histological and clinical analyses, USP39 may play a role in the regulation of patient’s response to carboplatin treatment. Thus, to clarify the possible mechanisms involved in the expression level of USP39 in regulating the apoptosis induced by carboplatin in ovarian cancer cells, flow cytometry was performed and the expression of apoptosis-associated proteins was examined. USP39 deficiency significantly potentiated the apoptotic rate induced by carboplatin in the SKOV3 cells, whereas USP39 overexpression markedly inhibited the apoptotic rate of the ES2 cells (Fig. 6A and C). Consistent with the effects observed on the cell apoptotic rate exerted by USP39, higher levels of cleaved PARP and cleaved caspase-3 were observed in the ES2 cells in which USP39 was silenced than in the control cells (Fig. 6B). By contrast, USP39 overexpression in the SKOV3 and ES2 cells significantly suppressed carboplatin-induced apoptosis, as demonstrated by the marked decrease in cleaved PARP and cleaved caspase-3 levels (Fig. 6D). These data indicate that USP39 plays an important role in mediating the sensitivity of ovarian cancer cells to carboplatin.

**USP39 knockdown reverses the promoting effects of USP39 on the chemosensitivity of the ovarian cancer cells to carboplatin, and on migration and invasion.** Rescue assays were conducted to prove the function of USP39 in the chemosensitivity of ES2 cells to carboplatin, and its effects on migration and invasion. As shown in Fig. 7A and B, shUSP39#1 partly attenuated the promoting effects of USP39 on the chemosensitivity of the cells to carboplatin, as evidenced by the increased cell apoptotic rate, and the increased expression of cleaved PARP and cleaved caspase-3 in the shUSP39#1-transduced cells. Moreover, cell migration and invasion promoted by USP39 was partially recovered by shUSP39#1 (Fig. 7C). Taken together, these findings demonstrated USP39 promoted the chemoresistance of ovarian cancer to carboplatin, as well as migration and invasion.

Expression level of USP39 influences the chemosensitivity of ES2 and SKOV3 cells to carboplatin in vivo. To further validate the in vitro results, the present study examined the effects of USP39 on the chemosensitivity of ES2 and SKOV3 cells in vivo. Mice were randomly divided into 4 groups (n=6/group). The results revealed that the ectopic expression of USP39 significantly increased tumor size. Carboplatin treatment markedly suppressed the growth of ES2 cells in the animal model. The overexpression of USP39 led to a more rapid growth rate with carboplatin treatment (Fig. 8A-C). Mice were randomly divided into 6 groups (n=8/group). The results revealed that the knockdown of USP39 reduced tumor burden and carboplatin treatment markedly suppressed the growth of SKOV3 cells in the animal model (Fig. 9). IHC revealed a lower level of cleaved caspase-3 in the USP39-overexpressing cells than in the control cells treated with carboplatin.
These results suggested that USP39 attenuated the chemosensitivity to carboplatin administration. To further investigate the role of USP39 in ovarian cancer metastasis, an experimental murine peritoneal metastasis model was used. The overexpression of USP39 in the ES2 cells promoted the formation of peritoneal metastases (Fig. 8E and F). Taken together, these results demonstrate that USP39 promotes the malignant phenotype of ovarian cancer cells.

Discussion

As one of the most common gynecological malignancies, ovarian cancer is a major contributor to the high rate of mortality associated with cancer among women due to the absence of methods for early diagnosis of this disease (16,17). Thus far, platinum-based chemotherapy is the most common strategy for ovarian cancer post-operative chemotherapy (18). To the best of our knowledge, therapeutic resistance is one of the major obstacles to the successful treatment of ovarian cancer (19,20). Although remarkable advances have been made in the understanding of the basic mechanisms of cancer over the past decades, the mechanisms of tumor progression and therapy resistance have not yet been entirely determined (21). Thus, there are numerous candidate biomarkers under development to evaluate their efficacy in the treatment of ovarian cancer (22).

The dysregulation of splicing factors has been reported to be associated with cancer development. For example, RNA binding motif protein 4 (RBM4) has been shown to be markedly decreased in patients with cancer (23,24), while serine and arginine rich splicing factor 1 (SRSF1) has been shown to be highly upregulated in breast and colon cancer (25,26). In this study, the analysis of patients with ovarian cancer that exhibited an overexpression of the spliceosome factor, USP39, suggested that USP39 was involved in carboplatin treatment and USP39 was identified as a potential biomarker of chemotherapeutic resistance in ovarian cancer.

To further confirm our clinical research and explore the biological function of USP39, the effects of USP39 were observed in SKOV3 and ES2 cells. The results helped to uncover the mechanisms of action of USP39 that affect the phenotypes of ovarian cancer cells. Chemotherapeutic treatment resistance could be overcome by the knockdown of USP39. In this study,
we demonstrated that the shRNA-mediated downregulation of USP39 resulted in attenuated cell proliferation and colony formation, whereas USP39 overexpression led to an enhanced cell proliferation and colony formation. As stated in a previous study, USP39 participated in the control of cell proliferation, colony formation and apoptosis through PARP cleavage in U2OS cells (27). Previous studies have shown that the induction of G2/M phase arrest contributes to alterations in the expression of cell cycle regulatory proteins. The knockdown of USP39 was previously identified to arrest progression of the cell cycle at G2/M phase accompanied by upregulation of p21 (27). In addition, a similar effect was detected in human SMMC-7721 cells, along with the inhibition of Cdc2 activity (28). Similarly, this study demonstrated that the knockdown of USP39 decreased the expression of cyclin B1, which controls the entrance into mitosis, thereby, accumulating the cell cycle in the quiescent G2/M phase. Although the upregulation of USP39 has been identified to be an oncogenic factor for tumor progression, its molecular mechanisms of action remain to be fully determined. In recent years, the mechanisms contributing to the dysregulation of oncogenes have been investigated (29). It has been reported that the phosphorylation of EGFR and its downstream signaling molecules, such as AKT and ERK can be activated, thereby promoting tumorigenesis and tumor progression (29). In this study, the results revealed that the overexpression of USP39 markedly induced the phosphorylation of EGFR, AKT and ERK. It has been demonstrated that the depletion of USP39 induces U2OS cell apoptosis by PARP cleavage, which is a reliable indicator of apoptosis (27). Notably, this study demonstrated that the silencing of USP39 promoted carboplatin-mediated apoptosis via PARP and caspase-3 cleavage. To validate the function of USP39 in ovarian cancer progression, rescue assays were carried out. The results revealed that the knockdown of USP39 attenuated the promoting effects of USP39 on cell chemosensitivity to carboplatin, migration and invasion, indicating the role of USP39 in ovarian cancer progression. In the in vivo experiments, the overexpression
Figure 8. Overexpression of USP39 reduces the sensitivity of ES2 cells to carboplatin and promotes tumor metastasis in vivo. (A) Images of the tumors in the xenograft model. (B) Tumor weight in each group. (C) Tumor volumes in the indicated groups were measured every 3 days. Data are presented as the means ± standard deviation. (D) The expression of USP39 and cleaved caspase-3 was analyzed by immunohistochemistry in control and USP39-overexpressing ES2 cells. Representative images are shown at x400 magnification. (E and F) Xenograft models of intraperitoneal metastasis. *P<0.05, **P<0.01, ***P<0.001. USP39, ubiquitin-specific protease 39; OE, overexpression.

Figure 9. Knockdown of USP39 increases the sensitivity of SKOV3 cells to carboplatin in vivo. (A) Images of the tumors in the xenograft model. (B) Tumor weight in each group. A total of 4x10^6 stably transfected SKOV3 cells were resuspended in 100 µl normal saline and injected subcutaneously into the flank of each mouse with a 28G syringe. At 3 days post-inoculation, carboplatin was administered to the mice by intraperitoneal injection at a dose of 50 mg/kg every 3 days for 3 consecutive times. *P<0.05, **P<0.01, ***P<0.001. USP39, ubiquitin-specific protease 39; sh, small hairpin.
of USP39 decreased the chemosensitivity of ES2 cells to carboplatin in subcutaneous xenograft models. By contrast, the knockdown of USP39 reduced the tumor burden. Due to the rapid and early metastasis to the peritoneum in ovarian cancer, it was concluded that USP39 was involved in metastasis in the peritoneal metastasis model. Based on these data, we hypothesized that USP39 promotes ovarian cancer chemoresistance and may thus serve as a therapeutic marker for ovarian cancer.

Taken together, in this study, using in vitro and in vivo approaches, the carcinogenic function of USP39 in ovarian cancer cells was observed for the first time, at least to the best of our knowledge. USP39 knockdown enhanced the sensitivity of ovarian cancer cells to carboplatin. Therefore, USP39 may be used for predicting patients with ovarian cancer who are at a high risk of developing resistance to carboplatin-based chemotherapy. Developing strategies with which to target USP39 may be useful for overcoming therapeutic resistance in patients with ovarian cancer. Several studies have reported a pre-mRNA splicing function for USP39 (7,10). Thus, genes involved in splicing and which are regulated by USP39 should be screened using splicing microarrays in future studies in order to elucidate the mechanisms of action of USP39 in mediating chemoresistance.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China (grant nos. 81650015, 81130043 and 81472452), and by the CAMS Initiative for Innovative Medicine (grant no. 2017-I2M-3-004).

Availability of data and materials

All data generated or analyzed during this study are included in this published article or are available from the corresponding author on reasonable request.

Authors' contributions

TC conceived the study. LW and TC designed and conducted the experiments. XL, WY andYL conducted data acquisition and data analysis. TC drafted the article and critically revised it for important intellectual content. ZL, HC and ZC contributed to refining the ideas, carrying out additional analyses, processing figures, and finalizing this article. All authors discussed the results, revised the manuscript and agree to be accountable for all aspects of the work. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

All patients provided informed consent to participate in the study. The study was approved by the ethics committee of the Chinese Academy of Medical Sciences Cancer Hospital (Beijing, China). Animal studies were approved by the Animal Care and Use Committee of Cancer Hospital, Chinese Academy of Medical Sciences.

Patient consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References


